Price T Rowe Associates Inc Verona Pharma PLC Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Verona Pharma PLC stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,833,532 shares of VRNA stock, worth $115 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,833,532
Previous 1,335,194
37.32%
Holding current value
$115 Million
Previous $38.4 Million
121.66%
% of portfolio
0.01%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding VRNA
# of Institutions
218Shares Held
67.5MCall Options Held
1.4MPut Options Held
299K-
Perceptive Advisors LLC New York, NY6.39MShares$401 Million9.9% of portfolio
-
Nea Management Company, LLC Timonium, MD5.58MShares$350 Million18.53% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.38MShares$212 Million9.42% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.13MShares$196 Million2.79% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx3.13MShares$196 Million2.81% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $3.82B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...